|Age:||I'm just over forty|
Multiple late-stage clinical trials for potential treatments have failed to produce the they needed to move forward, challenging elements of the amyloid hypothesis pursued by the majority of the field.
Meanwhile, as our population ages, the of patients diagnosed each year accelerates. The urgency of this situation is not lost on Guy Seabrook, Ph. Why is that? Our knowledge of the underlying cause of the disease grows every year, generating more insights into where and when we can intervene.
Investments are being made, and new collaborations are being forged. This information could lead to effective therapeutics as well as diagnostic tests to enable early detection, and thus allow earlier intervention.
Early detection would not only help improve outcomes, it would grant invaluable time to patients and their families. We are studying the three hallmarks of the illness — amyloid plaques, tau tangles, and synaptic recovery in the brain. By concentrating on these targets, we hope to find ways to slow disease progression or prevent the disease from leading to dementia and also to potentially recover brain function.
In addition, we have many scientific partnerships in this area, and we are working with governments and nonprofit organizations to address the economic and social impacts as well.